Invited Speakers

*Alphabetical order by first name

Plenary 1
February 22 (Mon), 09:15-09:55

Mano Manoharan USA

Alnylam Pharmaceuticals

TBD

Plenary 4
February 23 (Tue), 13:15-13:55

Bruce Sullenger USA

Duke University

Preclinical and Clinical Development of Anticoagulant and Thrombolytic Aptamers and Reversal Agents

Session 1
February 22 (Mon), 09:55-11:10

Jihye Park USA

Novo Nordisk

Harnessing the Promise of RNA Therapeutics

Takeshi Wada Japan

Tokyo University of Science

Development of New Molecular Technologies for siRNA Therapeutics



Session 2
February 22 (Mon), 11:30-12:35

Hiroshi Abe Japan

Nagoya University

Chemical Synthesis and Engineering of mRNA for Next-Generation Nucleic Acid Therapeutics



Session 3
February 22 (Mon), 14:15-15:35

Kumiko Ui-Tei Japan

Institute of Science Tokyo

Potent and Specific siRNA Design: From Sequence Rules to Structure-Guided Precision Therapeutics



Session 4
February 22 (Mon), 15:55-17:25

Long-Cheng Li China

Ractigen Therapeutics

RNAa: From Bench to Bedside—A 20-Year Journey

Ron Batra USA

Dyne Therapeutics

TBD



Session 5
February 23 (Tue), 09:40-10:55

S. Chul Kwon Hong Kong, China

The University of Hong Kong

High-Resolution RNA Knockdown Profiles of Small RNA and Cas13 Systems

Wensheng Wei China

Peking University

TBD



Lunch Seminar 2 [LS2]
February 23 (Tue), 12:15-13:15

Ralph Walker II USA

LGC Diagnostics & Genomics

From AI-Driven Discovery to Efficient RNA Synthesis: Advancing Productivity With MerMade Oligo Synthesizers and PrimeMax CPG Solid Support



Session 7
February 23 (Tue), 13:55-15:15

Ichiro Hirao Singapore

Xenolis Pte Ltd

Novel DNA Modality: Genetic Alphabet Expansion

Ryohei Kajino Japan

Luxna Biotech

Addressing key challenges in Oligonucleotide Therapeutics with Luxna Xeno Nucleic Acid (XNA) Technologies



Session 8
February 23 (Tue), 15:35-17:15

Ik-Hyeon Paik USA

Wave Life Sciences

From Chiral Monomers to Stereopure Oligonucleotides: Synthesis and NMR Characterization

Tae-Won Kim USA

Ionis Pharmaceuticals

Zilganersen in Alexander Disease: Translational Pharmacology, CNS Delivery, and Intrathecal Safety

Thomas Rupp Germany

Thomas Rupp Consulting UG

The Impurity Puzzle: Connecting Process, Quality, and Regulatory Strategy

Yogesh S. Sanghvi USA

Rasayan Inc.

TBD

TOP